Common Genetic Variants and Peritoneal Solute Transfer Rate in People with Kidney Failure Treated with Peritoneal Dialysis

A Genome-wide Association Study

Rajnish Mehrotra, MD, MS1, Ian B. Stanaway, PhD1, Gail P. Jarvik, MD, PhD2, Mark Lambie, BM BCh, PhD3, Johann Morelle, MD, PhD4, Jeffrey Perl, MD, SM5, Jonathan Himmelfarb, MD1, Olof Heimburger, MD, PhD6, David W. Johnson, PhD7, Talha H Imam, MD8, Bruce Robinson, MD, MS9, Peter Stenvinkel, MD, PhD6, Olivier Devuyst, MD, PhD4, Simon J. Davies, FRCP3 on behalf of the Bio-PD Consortium

1Kidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA

2Departments of Medicine (Medical Genetics) and Genome Sciences, University of Washington, Seattle, WA

3School of Medicine, Faculty of Medicine and Health Sciences, Keele University, Keele, UK

4Division of Nephrology, Cliniques universitaires Saint-Luc, Brussels, Belgium; and Institut de Recherche Experimentale et Clinique, UClouvain, Brussels, Belgium

5Division of Nephrology, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada

6Division of Renal Medicine, Department of Clinical Science, Intervention, and Technology, Karolinska Institute, Stockholm, Sweden

7Australasian Trials Network, University of Queensland, Brisbane, Australia

8Department of Nephrology, Kaiser Permanente, Fontana, CA

9Arbor Research Collaborative for Health, Ann Arbor, MI

**Number of Characters in Abstract:** 1486

**Number of Words in Text:** 4127

**Number of Figures:** 4

**Number of Tables:** 3

**Address for Correspondence:** Rajnish Mehrotra

 325 Ninth Ave, Box 359606

 Seattle, WA 98104

 Tel: 206-744-4933

 Email: rmehrotr@uw.edu

**Abstract**

Movement of solutes across the peritoneum allows for the use of peritoneal dialysis (PD) to treat kidney failure. There is a large inter-individual variability in the peritoneal solute transfer rate (PSTR). This study tested the hypothesis that common genetic variants are associated with variability in PSTR. Of the 3561 participants from 69 centers in six countries, 2850 with complete data were included in a genome-wide association study. PSTR was defined as the 4-h dialysate/plasma creatinine ratio from the first peritoneal equilibration test after starting PD. Heritability of PSTR was estimated using genomic-restricted maximum-likelihood (GREML) analysis, and the association of PSTR with a genome-wide polygenic risk score was also tested. The mean (± SD) 4-h D/P creatinine in participants was 0.70 (± 0.13). In participants of European ancestry (n=2212), no signal reached genome-wide significance but 23 single nucleotide variants (SNVs) at four loci demonstrated suggestive associations (p < 5 x 10-6) with PSTR. Meta-analysis of the ancestry stratified regressions (n=2850) revealed five SNVs at four loci with suggestive associations with PSTR. Association across ancestry strata was consistent for rs28644184 at the *KDM2B* locus. The estimated heritability of PSTR was 19% and the polygenic risk score was associated with PSTR (permuted model p-value, 0.008). This first GWAS for PD bolsters evidence for a genetic contribution to inter-individual variability in PSTR.

**Introduction**

In 2019, about 390,000 people with kidney failure were being treated with peritoneal dialysis (PD) comprising 11% of the dialysis patient population worldwide1. Since PD provides similar short- and long-term survival as in-center hemodialysis often at lower societal costs, the use of PD is anticipated to further expand in many parts of the world including the United States2, 3. This growing patient population underscores the need to better understand the biology that allows the peritoneum to serve as a dialysis membrane. This, in turn, will facilitate the development of biomarkers to monitor peritoneal health and treatments to enhance solute or fluid removal or mitigate peritoneal damage associated with long-term PD.

PD utilizes the diffusive and convective movement of solutes across the peritoneum to manage uremia. The peritoneal solute transfer rate (PSTR) is routinely measured in clinical practice with a peritoneal equilibration test (PET) and it is highly reproducible. PSTR is described as the ratio of the concentration of creatinine in the dialysate at four hours of a dwell of dialysate solution to that in the plasma (4-h D/P creatinine)4, 5. Large cohort studies have consistently shown that there is an over 3-fold inter-individual variability in PSTR (4-h D/P creatinine, 0.3-1.0) and demographic and clinical factors explain less than 10% of this variability6-10. The variability is clinically meaningful as it influences PD prescription, and a faster PSTR is associated with a higher risk for death or hospitalization5, 9, 11.

Experimental, clinical, and several candidate gene association studies suggest that some of this inter-individual variability in peritoneal function is heritable12-21. Thus far, human studies have had small sample sizes, they examined a limited range of genetic variability in few candidate genes, and have rarely been replicated. Genome-wide association studies (GWAS) provide an unbiased approach to identifying common genetic variants associated with a given phenotype and overcome many of the limitations of the candidate gene studies of peritoneal function to date22. However, no GWAS has been undertaken for any PD-related phenotype. To bridge this gap in knowledge, we undertook the Biological Determinants of PD (Bio-PD) study to perform a GWAS to test the hypothesis that common genetic variants explain some of the inter-individual variability in PSTR in people with kidney failure treated with PD.

**Methods**

***Study Population***

 The study cohort comprised participants with kidney failure treated with PD from 69 centers in six countries (Australia, Belgium, Canada, Sweden, United Kingdom, and United States) enrolled either prospectively for Bio-PD study (NCT02694068; n=1677), or by procuring frozen DNA of participants in other studies (n=1884).

 Participants in Bio-PD were prospectively enrolled from 54 centers in four countries (Australia, 2; Canada, 5; United Kingdom, 32; and United States, 15 centers) from September 2013 through November 2018. Ten of the 56 centers were also participating sites in the Peritoneal Dialysis Outcomes and Practice Patterns (PDOPPS) study; however, enrollment in PDOPPS was not required for enrollment in Bio-PD. All individuals treated with PD in participating facilities who had undergone a PET within six months of starting PD were eligible for enrollment, without regard to duration of PD treatment. There were no exclusion criteria. The overall plan for prospective enrollment was reviewed and approved by the Institutional Review Board (IRB) of the University of Washington, with additional approvals from IRBs or Ethics Boards of participating institutions as needed. All participants provided written informed consent for participation.

 DNA samples and phenotype data were also procured for participants enrolled through three different sources: (1) Peritoneal Dialysis Competitive Risk Analysis for Long-Term Outcomes (PD-CRAFT) that enrolled participants from 42 centers in the United Kingdom from August 2012 through December 2014 (n=1355), 31 of which also participated in prospective enrollment in Bio-PD study; (2) participants enrolled in an ongoing cohort study of peritoneal function in Belgium from November 1994 through March 2018 (n=314); and (3) longitudinal cohort study of incident patients with kidney failure in Sweden from February 1993 through August 2014 (n=215)23. The consent forms from these studies were reviewed by the IRB at the University of Washington to ensure that they allowed for use of genomic and phenotypic data for this current study.

***Phenotype, and Other Covariates***

The phenotype was PSTR, as described by the 4-h D/P creatinine from the first PET performed for clinical care after initiating PD. Covariates included age (years), sex, self-reported race, cause of kidney failure (diabetes, hypertension, glomerular disease, cystic kidney disease, other, or unknown), diabetes mellitus (yes/no), body mass index, interval from start of PD to PET in days (PD start-PET interval), tonicity of dextrose used for PET (1.5%, 2.5%, or 4.25%), and country of enrollment.

***Genome-wide genotyping and imputation***

Of the 3561 study participants, blood samples were collected and available for 3470 individuals (Figure 1). DNA was purified using a non-enzymatic method from either whole blood collected and stored frozen in PAXgene blood DNA tubes, or from buffy coat24. The details of the method for DNA extraction are summarized in the Supplemental Methods. The amount of DNA was insufficient for 45 participants, and the sample failed quality control for an additional 414 participants (Figure 1 and Supplemental Table 1). Hence, genome-wide genotyping was completed and available for 3010 participants and performed in two batches at the Northwest Genomic Center at the University of Washington. The first batch (n=1957) was genotyped on the InfiniumOmni2-5-8v1-3\_A1 array with 2,372,784 single nucleotide variants (SNVs). The second batch (n=1053) was genotyped on the InfiniumOmni2-5-8v1-4\_A1 array with 2,382,209 SNVs. For quality control, we removed subjects with duplicated sample-subject IDs between batches that were genotype discordant and sex discordant upon comparison of the heterozygosity of the X chromosome to reported sex. Each batch was also filtered for missingness of genotype call rates using plink -geno 0.02 -mind 0.02 and prepared for imputation of SNVs using the Michigan Imputation Server and the HRC1.1 SNV reference panel25-27. The resulting imputed genotype files (VCFs) were merged using bcftools and converted to plink bfiles for analysis28, 29. The mean of the r2 imputation quality information scores for each variant from the two batches were calculated and a threshold of r2 > 0.3 was used as the minimum imputation quality for including SNV in the analyses.

Data from each autosomal chromosome was linkage-disequilibrium-pruned using the function (plink --maf 0.02 --geno 0.1 --mind 0.1 --indep-pairwise 1000 50 0.7) (plink v1.90b6.21) and we excluded the hg19 regions (chr5:44000000-51500000, chr6:25000000-33500000, chr8:8000000-12000000, chr11:45000000-57000000). These linkage-disequilibrium pruned files were then merged and identity-by-descent (IBD) (plink --genome) and principal component analyses (PCA) (plink --pca) were performed genome wide (Supplemental Figures 1 and 2, respectively). A homogeneous subset of 2212 participants self-reported “White” race and with European ancestry identified by kmean clustering was used to calculate the Hardy-Weinberg equilibrium statistics.

The IBD plot was inspected to identify and remove (1) apparent duplicates/twins, parent-child, sibling, or lower degree related individuals; and (2) related individuals with IBD0 < 0.83 or IBD1 > 0.1 (Supplemental Figure 1). Sixty-two participants with relatedness on IBD analyses were removed prior to analyses (Figure 1 and Supplemental Table 1). The PC1 and PC2 was plotted with an overlay of self-reported race categories and a visual inspection of the plot showed good concordance between the expected ancestry clusters and reported race (Supplemental Figure 2).

***Statistical Analyses***

Participants with missing data on the phenotype, 4-h D/P creatinine (n=89), and those with physiologically improbable values of 4-h D/P creatinine < 0.3 (n=4) or > 1.15 (n=5) were excluded from analyses (Figure 1 and Supplemental Table 1). The missing data for age (n=7), diabetes mellitus (n=401), body mass index (n=114), and PD start-PET interval (n=6), by ancestry, are summarized in Supplemental Table 2. Missing data were handled using five multiple imputations with a regression model with age, sex, diabetes mellitus, body mass index, 4-h D/P creatinine, and country of enrollment as predictors (Supplemental Table 3)30. The reported interval between PD start and PET was between -45 and +365 in 2601 (89%) of 2912 participants; it was < -45 d in 35 participants and > 365 d in 276 participants. Prior to inclusion in the regression model, data on this variable was winsorized and placed in the tails of the distribution in an ordered manner so as not to create artificial peaks in the histogram (Supplemental Methods)31. Furthermore, as the log of PD start-PET intervals yielded a more normal distribution than the untransformed values, we used log ((PD start-PET interval) + 100) in regression analyses and then centered and scaled these values for the resulting transformation.

As a first step in the analysis, we built a regression model using clinical covariates, with 4-h D/P creatinine as an outcome. The model was inspected using transformed, untransformed and bounded (range -45 to 365) PD start-PET interval variable, as well as with and without imputation of the missing data. If a covariate was significant in unadjusted analyses, or in any other modelling, it was included in the final model. Cause of kidney failure was not included in the final regression model due to collinearity with the covariate diabetes mellitus, and because adding it to the model resulted in little gain in model r-square.

For GWAS analyses, the clinical covariates of age, sex, diabetes mellitus, body mass index, log transformed PD start-PET interval, dialysate tonicity for PET, country of enrollment, and genomic PCA (PCs 1-10) were adjusted for in regressions, performed using mixed model analysis with the Genome-wide Complex Trait Analysis (GCTA, version 1.93.2 beta) software with the –mlma-loco genotype relationship matrix computation32-35. SNVs with low imputation quality (r2 ≤ 0.3) or out of Hardy-Weinberg Equilibrium (p-value < 10-6) in participants of European ancestry that also self-reported 'White’ were removed from the analysis. Common variants with minor allele frequency > 2% across all 2850 participants were included in additive (0/1/2) models. Ancestry-stratified analyses were undertaken in the sub-groups of participants with concordant self-reported and genetic ancestry (by k-means clustering): European (n=2212), African (n=181), Asian (n=109), and Admixed/Other (n=348). These analyses were adjusted for principal components of ancestry specific to the ancestral subset. The analyses were run five times, one with each set of imputed covariates and the resultant p-values were combined using the Median P-value Rule (MPR) to construct summary Manhattan and Quantile-Quantile (QQ) plots36, 37. Meta-analysis was performed to combine the resulting GWAS in four strata of ancestry using the METAL software (released on 2011-03-25)38. We excluded variants in strata for meta-analyses that had a minor allele count of ≤ 10 and where the effect allele, major allele, and minor allele did not harmonize using the EasyQC imputation preparation R package39. Variants with combined p-values < 5 x 10-8 were considered to have genome-wide significance and with combined p-values < 5 x 10-6 as suggestive40, 41.

Heritability was calculated using the GREML method as implemented in the Genome-wide Complex Trait Analysis (GCTA) software32-35. This was done using the continuous variable outcome methods, with a linkage disequilibrium (LD) score region of 200kb and stratified variants by quartiles for making the four genetic relationship matrices representing high to low LD. The same covariates were used for calculating heritability as for the GWAS. The mean of the heritability estimates of each of the imputed covariate versions and median p-value rule was used to obtain a single heritability estimate.

A genome-wide polygenic risk score (PRS) was developed for 4-h D/P creatinine by randomly holding out a 10.5% (n=299) subset of participants and then fitting betas with GWAS of the remaining 89.5% of the data in all participants without regard to ancestry, using five iterations of covariate imputations. The combined betas from the fitted GWASs and the same demographic and clinical covariates (age, sex, diabetes, body mass index, log transformed PD start-PET interval, dialysate tonicity for PET, country of enrollment, and principal components (PC) 1-10 of ancestry) were used to predict 4-h D/P creatinine in the held-out subset (n=299) using the polygenic risk score (PRSice version 2.2.6) software package which implements a LD pruning and p-value thresholding method to select the model SNVs42. A permutation (n=10,000) empirical test of the held-out data was performed to control over-fitting. Both the unadjusted primary and permuted empirical models are reported.

**Results**

***Characteristics of Study Participants***

Of the 3561 participants enrolled in the study, 2850 (80%) unrelated individuals, with adequate genotyping quality control and complete phenotypic characterization, were included in the analyses (Figure 1 and Supplemental Table 1). The excluded participants were more likely to be enrolled in the UK and have “other/unknown” as the cause of their kidney failure, but had similar 4-h D/P creatinine as compared with included participants (Supplemental Table 4). The demographic and clinical characteristics of the 2850 participants by ancestry are summarized in Table 1. The largest proportion of study participants (81%) were of European ancestry. Among the total study population across all ancestries, 55% were enrolled from the UK and 38% were women. The mean ± standard deviation 4-h D/P creatinine was 0.70 ± 0.13, it was obtained using a PET done at a median (interquartile range) of 63 (28, 120) days after PD start, and it was performed using 2.5% dextrose in 79% of participants.

The demographic and clinical variables explained 5.4% (95% confidence interval, 4.1%, 8.0%) of the variability in the 4-h D/P creatinine in participants with no missing data (n=2062) and 5.7% (95% confidence interval, 4.1%, 7.5%) using data with multiple imputation (n=2912).

***GWAS by Ancestry***

There were 7,066,544 SNVs which passed our quality parameters in participants of European ancestry with the lambda for genomic inflation of 0.991. The quantile-quantile (QQ) plots did not show any significant deviations from the expected p-values, implying there was no residual population stratification in the analyses (Supplemental Figure 3). No SNV reached genome-wide significance (p < 5 x 10-8) for association with 4-h D/P creatinine (Figure 2A and Table 2). The association of 23 SNVs at four loci reached the threshold for suggestive associations (p < 5 x 10-6) (Figure 2A and Table 2). The genomic inflation in analyses in individuals of African (n=181), Asian (n=109), and admixed/other ancestry (n=348) were 0.910, 0.773, and 0.854, respectively and the results of the GWAS by ancestry strata are summarized in Supplemental Table 5.

***Meta-Analysis of Ancestry-Stratified GWAS***

In the multi-ancestry meta-analyzed GWAS, 7,066,534 SNVs were included with a collective lambda of 0.963. Five SNVs at four loci reached the threshold for suggestive significance (Table 3); the coefficients for the estimates for the SNVs in the largest sub-groups by center (Belgium and Sweden) were similar to the entire study population (Supplemental Table 6). Two of the five SNVs (rs76108553 and rs111976243 at *LINC01800* locus) were among the 23 SNVs identified in the analyses limited to participants with European ancestry, and were supportive only with data from the sub-group of European ancestry in the meta-analysis (Table 3). The other three SNVs were identified only in the meta-analysis and not in analyses stratified by ancestry.

The SNVs had high imputation quality (all r2 ≥ 0.87); the r2 for 23 of the 26 SNVs identified either in the analyses in participants of European ancestry or meta-analysis, was ≥ 0.98. Each SNV had a minor allele frequency > 2% and five SNVs identified in the meta-analyses had a minor allele frequency of > 18%.

Of the five SNVs with suggestive associations, one was intronic in the protein coding gene *KDM2B,* three were in or near two long intergenic non-coding (LINC) RNAs (*LINC01800*, *and LINC01561*), and one SNV was in a region adjacent to the *KCNC2* gene*,* (Tables 2 and 3). The rs28644184 SNV in the *KDMB2* intronic region had evidence of expression quantitative trait loci (eQTLs) in the genotype-tissue expression (GTEx) data – the gene variants have been associated with differential expression of the index gene *KDM2B*. Figure 3A depicts the regional association plot of the region with *KDMB2* on chromosome 12 and Figure 3B presents the box plots for PSTR by *KDMB2* genotype .

Supplemental Figure 4 includes the regional association plots for the other genomic regions with suggestive associations. Supplemental Figure 5 presents the box plots for PSTR by genotype for the genes with suggestive associations in either the meta-analysis or individuals of European ancestry. The other biologic effects of the gene loci known to date are summarized in Supplemental Table 7.

***Mixed Model GWAS in the Entire Cohort adjusted for PCAs of ancestry***

 The results of the GWAS analyses in the entire cohort (n=2850), adjusted for principal components for ancestry, age, sex, diabetes, body mass index, dialysis tonicity used for the PET, PD start-PD interval, and country of enrollment are summarized in Supplemental Table 8 and Supplemental Figure 6. This analysis identified six SNVs in six genomic regions with suggestive associations and they included four of the five SNVs identified in the meta-analyses of ancestry-stratified data (rs76108553, rs2901257, rs117559199, and rs28644184). The lamda is 0.981.

***Heritability of 4-h D/P creatinine and Association with Polygenic Risk Score***

 The REML heritability of the phenotype was estimated at 19.3% (SE 17.3, p-value = 0.07). The polygenic risk score (PRS) GWAS was fitted with 2551 participants and the prediction was tested in 299 participants. LD pruning and p-value thresholding selected 36,357 SNVs at the 0.049 p-value threshold to be included in the PRS model. The PRS model explained 4.2% of the variance in 4-h D/P creatinine (primary model p-value, 0.0004; p-value for permutation test of data, 0.008). Figure 4 illustrates the relationship between the tertiles of PRS and 4-h D/P creatinine (n=299; p=0.0002 for difference across tertiles).

**Discussion**

 This first report of a GWAS in people with kidney failure treated with PD provides new insights into biological determinants of PSTR as described by 4-h D/P creatinine. While no association reached genome-wide significance, the SNVs at loci with suggestive associations highlight the potential significance of several mechanistic pathways in determining PSTR. This study also provides the first estimates on the heritability of the PSTR and its association D/P with a genome-wide PRS. These findings collectively bolster the evidence supporting the premise that a significant part of the inter-individual variability in PSTR is genetically determined.

 This international collaborative effort is the largest cohort study with bio-samples to date of patients with kidney failure treated with PD. The number of participants enrolled in this study is equal to about 1% of the entire point-prevalent population of patients treated with PD globally. The greatest challenge for studies of this kind is that a modest-sized patient population is dispersed in a few thousand centers around the world. In the United States, about 60,000 PD patients are presently treated in over 2500 dialysis facilities. Hence, even though the sample size for this GWAS is modest relative to that for other continuous polygenic traits such as eGFR or albuminuria, it required collaboration of 69 centers in six countries in three continents. Nevertheless, this first effort to undertake a GWAS to better understand peritoneal biology provides a strong foundation on which to build in the future.

 Even though none of the associations reached genome-wide significance, suggestive associations with five SNVs at four loci in the meta-analyses and the 21 SNVs at three loci in analyses of European ancestry may help our understanding of peritoneal biology. The peritoneum is a complex membrane that comprises a mesothelial cell mono-layer, and sub-mesothelial matrix with numerous embedded capillaries that participate in dialysis with PD43. Biopsy studies have indicated that the peritoneum of humans with kidney failure is thicker and has a higher density of capillaries than in those with normal kidney function44. These processes are substantially amplified with treatment with PD44. There is evidence that several of the SNVs with suggestive association in our study influence some of the mechanistic pathways relevant for peritoneal fibrosis and neo-vascularization with uremia and/or treatment with PD45.

Peritoneal fibrosis is the process that underlies the thickening of the peritoneum with uremia and following exposure to PD. Experimental evidence has suggested that epithelial-mesenchymal transition (EMT) of mesothelial cells is an important mechanistic pathway leading to peritoneal fibrosis45. There is laboratory evidence linking the *KDM2B* (meta-analyses) and *PCHD9* (European ancestry) genes with EMT. For example, upregulation of epigenetic factors such as *KDM2B* facilitates the metabolic switch from oxidative phosphorylation to glycolysis and EMT in mouse embryonic fibroblasts46. *PCDH9* has been shown to be an inhibitor of EMT in cancer and the down-regulation of *PCDH9* is a poor prognostic factor47, 48. Whether any of these variants influence EMT in peritoneal mesothelial cells and peritoneal fibrosis has not been studied and needs further study.

Our study also identified suggestive associations of PSTR with SNVs in loci for long non-coding RNAs (lncRNAs); two of the three SNVs had suggestive associations with PSTR in both the meta-analyses and analyses limited to participants of European ancestry. The lncRNAs are non-coding RNAs ranging in length from 200 nt to about 100 kb and are involved in multiple biologic processes, such as proliferation, differentiation, migration, and apoptosis49. There is also growing evidence that lncRNAs may play a role in PD-induced peritoneal fibrosis. For instance, in a microarray analysis of the peritoneum in a mouse model of PD-fluid induced peritoneal fibrosis, there was differential expression of 232 lncRNAs when compared with normal mouse peritoneum – 127 were upregulated and 105 were down-regulated50. Cell culture or animal studies have identified lncRNAs such as AV310809 as promoters or AK089579 and 6030408B1RIK as inhibitors of EMT of peritoneal mesothelial cells51-53. In conjunction with these prior studies, our findings underscore the potential importance of lncRNAs in peritoneal biology and pathobiology.

There is compelling evidence for the importance of intraperitoneal inflammation, particularly IL-6, in influencing the variability in PSTR8, 12. Recent evidence indicates that *KDM2B* is required for the induction of IL-6 in macrophages and dendritic cells, independent of its demethylase activity54. Whether this SNV influences intraperitoneal inflammation and PSTR is currently not known and requires further investigation. *KDM2B* is also involved in angiogenesis, another potential mechanistic pathway that could influence PSTR55.

In addition to these mechanistic insights, our study confirms our prior finding that demographic and clinical factors explain < 10% of the inter-individual variability in PSTR9. More importantly, our results indicate that genetic variation may explain 19% of the variability in PSTR. Furthermore, our findings show a genome-wide polygenic risk score that captured 4.2% of the variance in the phenotype, was associated with the 4-h D/P creatinine. Taken together, these data support the premise that genetic variation is an important determinant of inter-individual variability in PSTR and provides a a strong basis for further research.

 Our study has several important strengths. This is the first GWAS for peritoneal function and the first report of an estimate of heritability of the trait. The study is an international collaborative effort that enrolled participants from 69 centers in six countries and hence, our findings have significant external validity. The external validity of our findings is further underscored by the observation that the distribution of 4-h D/P creatinine in our cohort is similar to what has been reported in previous large PD patient populations and was similar in participants from different parts of the world in the study. Even though the vast majority of participants were of European ancestry, a significant minority of the participants were racial/ethnic minorities and this further increase the validity of our findings.

Notwithstanding its strengths, our study has several weaknesses. The phenotype was measured in several individual laboratories around the world, with different tonicities of dialysate with varying intervals from the time of start of PD. This variability in ascertaining the phenotype may have led to some loss in precision of the phenotype. Furthermore, our study is focused on a transfer rate of a single solute and did not include associations with ultrafiltration capacity. The study was under-powered to identify SNVs with genome-wide significance and the SNVs with suggestive associations may be false positives. The cohort comprised people primarily of European descent and our findings may not extend to other populations. There was also no other cohort available for independent replication of our findings and this will need to be done in future studies.

In conclusion, this study provides several lines of evidence to support the premise that genetic variations underlie a significant component of the inter-individual variability in PSTR seen in people starting treatment with PD. Our analyses in participants of European ancestry and meta-analyses across ancestry strata identified several SNVs with suggestive associations with 4-h D/P creatinine. Experimental evidence suggests that several of these loci include genes that are linked to mechanistic processes, such as EMT, that leads to peritoneal fibrosis, or inflammation or angiogenesis that influences PSTR. Our findings suggest that genetic variation may explain 19% of the variability in the trait and provide evidence for significant association of a genome-wide polygenic risk score with the phenotype. These findings require replication, meta-analysis of findings from our study with those with other cohorts, and mechanistic work to link SNVs and biologic pathways identified herein to peritoneal pathobiology.

**Members of the Bio-PD Consortium**

**PDOPPS**

Arbor Research Collaborative for Health, Ann Arbor Ronald Pisoni, Bruce Robinson

**Australia (No. of Clinical Centers, 2)**

1. Princess Alexandra Hospital, Brisbane David Johnson, Yeoungjee Cho
2. Royal Northshore Hospital, Sydney Muh Geot Wong, Amanda Mather,

Bruce Cooper

**Belgium (No. of Clinical Centers, 3)**

1. Cliniques universitaires Saint-Luc, Brussels Olivier Devuyst, Johann Morelle,

Eric Goffin

1. University Hospitals Leuven, Leuven Bert Bammens
2. CHC Liège, Liège Philippe Bovy

**Canada (No. of Clinical Centers, 5)**

1. St. Joseph’s Hospital, Hamilton Peter Margetts
2. St. Michael’s Hospital, Toronto Jeffrey Perl
3. St. Paul’s Hospital, Vancouver Paul Taylor
4. Victoria Hospital, London Arsh Jain
5. University Health Network, Toronto Vanita Jassal

**Sweden (No. of Clinical Centers, 1)**

1. Karolinska University Hospital, Stockholm Peter Stenvinkel, Olof Heimburger

**United Kingdom (No. of Clinical Centers, 43)**

1. Altnagelvin Area Hospital, Londonderry, N. Ireland Ying Kuan
2. Antrim Area Hospital, Antrim, N. Ireland Camille Harron
3. Birmingham Heartlands Hospital, Birmingham Indranil Dasgupta
4. Bradford Royal Infirmary, Bradford John Stoves, Habib Akbani
5. Broomfield Hospital, Chelmsford Sumith Abeygunasekara
6. Churchill Hospital, Oxford Edward Sharples
7. Cumberland Infirmary, Carlisle Paul Mead, Amer Hayat
8. Daisy Hill Hospital, Newry, Northern Ireland Neal Morgan
9. Derriford Hospital, Plymouth Hilary Cramp
10. Dumfries and Galloway Royal Infirmary, Dumfries Susan Robertson
11. Freeman Hospital, Newcastle upon Tyne Richard Fielding
12. Hammersmith Hospital, London Edwina Brown
13. Hull Royal Infirmary, Hull Helen Collinson
14. Ipswich Hospital NHS Trust, Ipswich Pravene Ande
15. Kent and Canterbury Hospital, Canterbury Tim Doulton
16. Kings College Hospital, London Iain MacDougall, Hugh Cairns
17. Lister Hospital, Stevenage Enric Vilar
18. Manchester Royal Infirmary, Manchester Anand Vardhan
19. Morriston Hospital, Swansea James Chess
20. New Cross Hospital, Wolverhampton Kanwaljit Sandhu
21. Northern General Hospital, Sheffield Martin Wilkie
22. Nottingham University Hospital, Nottingham Gavin McHaffie
23. Queen Alexandra Hospital, Portsmouth Robert Lewis
24. Queen Elizabeth Hospital, Birmingham Lavanya Kamesh
25. Queen Margaret Hospital, Dunfermline Kate Buck
26. Raigmore Hospital, Inverness Robert Peel
27. Royal Bournesmouth, Dorset Jo Taylor
28. Royal Cornwall Hospital, Cornwall Paul Johnston
29. Royal Derby Hospital, Derby Janson Leung
30. Royal Devon and Exeter Hospital, Exeter Coralie Bingham
31. Royal Liverpool & Broadgreen Univ. Hospital, Liverpool Hameed Anijeet
32. Royal Preston Hospital, Preston Ramzana Asghar
33. Royal Shrewsbury Hospital, Shrewsbury Satish Ranakrishna, Sunita Nair
34. Royal Sussex County Hospital, Brighton Neil Iggo
35. Salford Royal, Manchester David Lewis
36. Southmead Hospital, Bristol Uday Udayaraj, Susan Dawson
37. St. James’s University Hospital, Leeds Graham Woordrow
38. University Hospital Aintree, Liverpool Thangavelu Chandrasekar
39. University Hospital Coventry & Warwikshire, Coventry Rizwan Hamer
40. University Hospital, Liecester Jonathan Barratt, Richard Baines
41. University Hospital of North Midlands, Stoke-on-Trent Simon Davies
42. University Hospital of Wales, Cardiff, Wales Kieron Donovan
43. York Hospital, York Colin Jones

**United States (No. of Clinical Centers, 15)**

1. Dialysis Clinic, Inc. Nashville Christina Ynares
2. Houston Street Dialysis Center, San Antonio Carl Dukes
3. Kaiser Foundation Hospital, Fontana Talha H Imam
4. Massachusetts General Hospital, Boston Kristin Corapi, Sagar Nigwekar
5. San Diego Institute of Medical Research, San Diego Osman Khawar
6. Tufts University, Boston Daniel Weiner
7. University of California-Irvine, Irvine Wei Ling Lau, Kevin Harley
8. University of Southern California, Los Angeles Arshia Ghaffari
9. University of Texas Southwestern, Dallas Ramesh Saxena
10. University of Utah, Salt Lake City Josephine Abraham
11. University of Washington, Seattle Rajnish Mehrotra, Jonathan

Himmelfarb

1. Vanderbilt University, Nashville Kerri L. Cavanaugh, Thomas A

Golper

1. Wake Forest University, Winston-Salem John M. Burkart, James L. Pirkle
2. Washington University, St. Louis Brent Miller, Judy Jang
3. Yale University Jeffrey Turner

**Data Sharing Statement**

 The investigators are working with the NIH to deposit the phenotype-genotype data from participants enrolled prospectively in Australia, Canada, and the United States to the database of Genotype and Phenotypes (dbGaP). The request has already been submitted, and an accession ID is currently pending.

 The Institutional Review Board of the University of Washington and the Ethics Boards of participating institutions have determined that the data from participants in Belgium, Sweden, and the United Kingdom is not eligible for submission in a public data repository in either the United States or Europe. Since the participants did not sign a consent for their data to be deposited in a public repository, it has been deemed that doing so will serve no lawful purpose under the European Union General Data Protection Regulation (EU-GDPR).

**Acknowledgements**

The work described in this manuscript has been supported by a grant R01DK09915 from the NIH. Reruitment for PD-CRAFT between 2012 and 2015 was supported by a grant from the National Institute of Health Research (UK), PB-PG-0601-22456. The authors thank all the patients who participated in the studies included in these analyses. We are grateful to the members of the research team at the University of Washington that coordinated the international study (Anne Goodling, John Kundzins, Lori Linke, and Linda Manahan) and provided laboratory support (John Ruzinski and Jane Ranchalis), the staff that coordinated the study in Canada (Andrea Rathe-Skafel and Megan Freeman), and the team members that oversaw the research in the United Kingdom (Louise Phillips-Darby and the staff at the Clinical Trials Unit at Keele University). The authors wish to thank the team at Northwest Genomics Center at the University of Washington and IMPROVE-PD, a program funded by the Horizon 2020 Framework Program of the European Union through the Marie Sklodowska-Curie Programme as an Innovative Training Nework (ITN-ETN). The list of key contributors for each participating center is listed in the Supplemental Materials.

**Disclosures**

**Rajnish Mehrotra** has received honoraria from Baxter Healthcare.

**Ian B. Stanaway** has nothing to disclose.

**Gail Jarvik** has nothing to disclose.

 **Mark Lambie** reports honoraria from Baxter Healthcare, Fresenius Medical Care, and NxStage and a research grant from Baxter Healthcare outside the submitted work.

**Johann Morelle** reports speaker honoraria from Baxter Healthcare and Fresenius Medical Care, travel grants from Sanofi-Genzyme, consultancy fees from AstraZeneca and Alexion Pharmaceuticals, and research grants from Baxter Healthcare and Alexion Pharmaceuticals outside the submitted work.

**Jeffrey Perl** has received speaking honoraria from Astra Zeneca, Baxter Healthcare, DaVita Healthcare Partners, Fresenius Medical Care, Dialysis Clinic, Inc., Satellite Healthcare, and has served as a consultant for Astra Zeneca, Otsuka, Baxter Healthcare, DaVita Healthcare Partners, Fresenius Medical Care, and LiberDi.

**Jonathan Himmelfarb** is a founder and has equity interest in Kuleana Technology, Inc., a portable/wearable dialysis company.

**Olof Heimburger** has received consultancy fees and speaker’s honoraria from Baxter Healthcare, Astra Zeneca, Fresenius Medical Care, Adcock Ingram, Vifor, Opterion, and Gilead.

**David Johnson** has received consultancy fees, research grants, speakers’ honoraria, and travel sponsorships from Baxter Healthcare and Fresenius Medical Care, consultancy fees from Astra Zeneca, Bayer, and AWAK, speaker’s honoraria and travel sponsorships from ONO, and travel sponsorships from Amgen. He is a current recipient of an Australian National Health and Medical Research Council Practitioner Fellowship.

**Talha Imam** has nothing to disclose.

**Bruce Robinson** has received consultancy fees or travel reimbursement from AstraZeneca, GlaxoSmithKline, and Kyowa Kirin Co., all paid directly to his institution of employment.

**Peter Stenvinkel** has received consultancy fees, research grants, speaker’s honoraria from Baxter Healthcare, Astra Zeneca, Reata, Vifor, Fresenius Medical Care, Pfizer, Astellas, and Bayer.

**Olivier Devuyst** has received research funding from Baxter Healthcare, Otsuka Pharmaceuticals, and Galapagos, outside of the current submission.

**Simon Davies** has received research funding and honoraria from Baxter HealthCare and research funding from Fresenius Medical Care.

**Supplemental Materials Table of Contents**

**Supplemental Methods:** DNA Extraction and Approach to winsorization of PD start-PET interval variable

**Supplemental Table 1:** Number of participants, stratified by country, at each sequential step to be included in the analytic cohort

**Supplemental Table 2:** Number of participants with missing data on covariates stratified by ancestry

**Supplemental Table 3:** Comparison of summary characteristics of covariates in sub-group with complete data and with each of the five sets of multiple imputation used in the analyses

**Supplemental Table 4:** Comparison of demographic and clinical characteristics of participants excluded with those included in the analyses

**Supplemental Table 5:** Association of single nucleotide variants with suggestive associations identified in the meta-analysis, by ancestry

**Supplemental Table 6:** Association of single nucleotide variants with suggestive associations identified in the meta-analysis, in sub-groups of individuals of European ancestry from the largest enrolling centers

**Supplemental Table 7:** Gene function related biology in the reported suggestive genes identified either in the meta-analyses of ancestry-stratified data, or in participants of European ancestry

**Supplemental Table 8:** GWAS analyses in the entire cohort, adjusted for principal components for ancestry

**Supplemental Figure 1:** Identity by descent (IBD) plot of all pair-wise comparisons of genetic relatedness

**Supplemental Figure 2:** Principal component analysis (PCA) of the autosomal variants to determine genetic ancestry

**Supplemental Figure 3:** QQ plot of GWAS in participants of European ancestry, adjusted for principal components of ancestry in the group using the GCTA software with the -mlma-loco option.

**Supplemental Figure 4:** Regional association plot of genomic regions with single nucleotide variants with suggestive associations (panels A-F)

**Supplemental Figure 5:** Box plots for PSTR by genotype of variants identified to have suggestive associations in either the meta-analysis or in GWAS in participants of European ancestry (panels A-F)

**Supplemental Figure 6:** Results of genome wide association study (GWAS) in the entire cohort, adjusted for principal components for ancestry as – log10 p plot (Manhattan plot).

**Contributors:** List of key contributors from each participating center

**References**

1. Fresenius Medical Care. Annual Report 2019. 2019.

2. Mehrotra R, Devuyst O, Davies SJ*, et al.* The Current State of Peritoneal Dialysis. *J Am Soc Nephrol* 2016; **27:** 3238-3252.

3. Mehrotra R. Advancing American Kidney Health: An Introduction. *Clin J Am Soc Nephrol* 2019; **14:** 1788.

4. Twardowski ZJ, Nolph KD, Khanna R*, et al.* Peritoneal equilibration test. *Perit Dial Bull* 1987; **7:** 138-148.

5. Morelle J, Stachowska-Pietka J, Oberg C*, et al.* ISPD Recommendations for the evaluation of peritoneal membrane dysfunction in adults: classification, measurement, interpretation, and rationale for intervention. *Perit Dial Int* 2021; **41:** in press.

6. Mujais S, Vonesh E. Profiling of peritoneal ultrafiltration. *Kidney Int Suppl* 2002**:** S17-22.

7. Rumpsfeld M, McDonald SP, Johnson DW. Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. *J Am Soc Nephrol* 2006; **17:** 271-278.

8. Lambie M, Chess J, Donovan KL*, et al.* Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. *J Am Soc Nephrol* 2013; **24:** 2071-2080.

9. Mehrotra R, Ravel V, Streja E*, et al.* Peritoneal Equilibration Test and Patient Outcomes. *Clin J Am Soc Nephrol* 2015; **10:** 1990-2001.

10. La Milia V, Cabiddu G, Virga G*, et al.* Peritoneal Equilibration Test Reference Values Using a 3.86% Glucose Solution During the First Year of Peritoneal Dialysis: Results of a Multicenter Study of a Large Patient Population. *Perit Dial Int* 2017; **37:** 633-638.

11. Brimble KS, Walker M, Margetts PJ*, et al.* Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. *J Am Soc Nephrol* 2006; **17:** 2591-2598.

12. Gillerot G, Goffin E, Michel C*, et al.* Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. *Kidney Int* 2005; **67:** 2477-2487.

13. Margetts PJ, Hoff C, Liu L*, et al.* Transforming growth factor beta-induced peritoneal fibrosis is mouse strain dependent. *Nephrol Dial Transplant* 2013; **28:** 2015-2027.

14. Szeto CC, Poon P, Szeto CY*, et al.* Plasminogen activator inhibitor-1 4G/5G genetic polymorphism does not affect peritoneal transport characteristic. *Am J Kidney Dis* 2002; **39:** 1061-1067.

15. Wong TY, Szeto CC, Szeto CY*, et al.* Association of ENOS polymorphism with basal peritoneal membrane function in uremic patients. *Am J Kidney Dis* 2003; **42:** 781-786.

16. Szeto CC, Chow KM, Poon P*, et al.* Genetic polymorphism of VEGF: Impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients. *Kidney Int* 2004; **65:** 1947-1955.

17. Akcay A, Micozkadioglu H, Atac FB*, et al.* Relationship of ENOS and RAS gene polymorphisms to initial peritoneal transport status in peritoneal dialysis patients. *Nephron Clin Pract* 2006; **104:** c41-46.

18. Maruyama Y, Numata M, Nakayama M*, et al.* Relationship between the -374T/A receptor of advanced glycation end products gene polymorphism and peritoneal solute transport status at the initiation of peritoneal dialysis. *Ther Apher Dial* 2007; **11:** 301-305.

19. Ebinc FA, Derici U, Gonen S*, et al.* TGF-beta1 gene polymorphisms and peritoneal equilibration test results in CAPD patients. *Ren Fail* 2008; **30:** 15-19.

20. Hwang YH, Son MJ, Yang J*, et al.* Effects of interleukin-6 T15A single nucleotide polymorphism on baseline peritoneal solute transport rate in incident peritoneal dialysis patients. *Perit Dial Int* 2009; **29:** 81-88.

21. Lee YT, Tsai YC, Yang YK*, et al.* Association between interleukin-10 gene polymorphism -592 (A/C) and peritoneal transport in patients undergoing peritoneal dialysis. *Nephrology (Carlton)* 2011; **16:** 663-671.

22. Manolio TA. Genomewide association studies and assessment of the risk of disease. *N Engl J Med* 2010; **363:** 166-176.

23. Stenvinkel P, Heimburger O, Paultre F*, et al.* Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. *Kidney Int* 1999; **55:** 1899-1911.

24. Lahiri DK, Nurnberger JI, Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. *Nucleic Acids Res* 1991; **19:** 5444.

25. Das S, Forer L, Schonherr S*, et al.* Next-generation genotype imputation service and methods. *Nat Genet* 2016; **48:** 1284-1287.

26. Loh PR, Danecek P, Palamara PF*, et al.* Reference-based phasing using the Haplotype Reference Consortium panel. *Nat Genet* 2016; **48:** 1443-1448.

27. McCarthy S, Das S, Kretzschmar W*, et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet* 2016; **48:** 1279-1283.

28. Chang CC, Chow CC, Tellier LC*, et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* 2015; **4:** 7.

29. Li H, Handsaker B, Danecek P*, et al.*: BCFtools. In (vol 2020), 2020

30. van buuren s, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. *J Stat Softw* 200; **45:** 1-67.

31. Hastings C, Mosteller F, Tukey JW*, et al.* Low moments for small samples: a comparative study of order statistics. *Ann Math Stat* 1947; **18:** 413-426.

32. Yang J, Lee SH, Goddard ME*, et al.* GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet* 2011; **88:** 76-82.

33. Yang J, Manolio TA, Pasquale LR*, et al.* Genome partitioning of genetic variation for complex traits using common SNPs. *Nat Genet* 2011; **43:** 519-525.

34. Yang J, Benyamin B, McEvoy BP*, et al.* Common SNPs explain a large proportion of the heritability for human height. *Nat Genet* 2010; **42:** 565-569.

35. Yang J, Bakshi A, Zhu Z*, et al.* Genetic variance estimation with imputed variants finds negligible missing heritability for human height and body mass index. *Nat Genet* 2015; **47:** 1114-1120.

36. Eekhout I, van de Wiel MA, Heymans MW. Methods for significance testing of categorical covariates in logistic regression models after multiple imputation: power and applicability analysis. *BMC Med Res Methodol* 2017; **17:** 129.

37. van de Wiel MA, Berkhof J, van Wieringen WN. Testing the prediction error difference between 2 predictors. *Biostatistics* 2009; **10:** 550-560.

38. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 2010; **26:** 2190-2191.

39. Winkler TW, Day FR, Croteau-Chonka DC*, et al.* Quality control and conduct of genome-wide association meta-analyses. *Nat Protoc* 2014; **9:** 1192-1212.

40. Hoggart CJ, Clark TG, De Iorio M*, et al.* Genome-wide significance for dense SNP and resequencing data. *Genet Epidemiol* 2008; **32:** 179-185.

41. Sham PC, Purcell SM. Statistical power and significance testing in large-scale genetic studies. *Nat Rev Genet* 2014; **15:** 335-346.

42. Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data. *Gigascience* 2019; **8**.

43. Contreras-Velazquez JC, Soto V, Jaramillo-Rodriguez Y*, et al.* Clinical outcomes and peritoneal histology in patients starting peritoneal dialysis are related to diabetic status and serum albumin levels. *Kidney Int Suppl* 2008**:** S34-41.

44. Williams JD, Craig KJ, Topley N*, et al.* Morphologic changes in the peritoneal membrane of patients with renal disease. *J Am Soc Nephrol* 2002; **13:** 470-479.

45. Devuyst O, Margetts PJ, Topley N. The pathophysiology of the peritoneal membrane. *J Am Soc Nephrol* 2010; **21:** 1077-1085.

46. Sun H, Yang X, Liang L*, et al.* Metabolic switch and epithelial-mesenchymal transition cooperate to regulate pluripotency. *EMBO J* 2020; **39:** e102961.

47. Zhu P, Lv J, Yang Z*, et al.* Protocadherin 9 inhibits epithelial-mesenchymal transition and cell migration through activating GSK-3beta in hepatocellular carcinoma. *Biochem Biophys Res Commun* 2014; **452:** 567-574.

48. Wang C, Yu G, Liu J*, et al.* Downregulation of PCDH9 predicts prognosis for patients with glioma. *J Clin Neurosci* 2012; **19:** 541-545.

49. Marques AC, Ponting CP. Catalogues of mammalian long noncoding RNAs: modest conservation and incompleteness. *Genome Biol* 2009; **10:** R124.

50. Liu Y, Guo R, Hao G*, et al.* The expression profiling and ontology analysis of noncoding RNAs in peritoneal fibrosis induced by peritoneal dialysis fluid. *Gene* 2015; **564:** 210-219.

51. Zhang XW, Wang L, Ding H. Long noncoding RNA AK089579 inhibits epithelial-to-mesenchymal transition of peritoneal mesothelial cells by competitively binding to microRNA-296-3p via DOK2 in peritoneal fibrosis. *FASEB J* 2019; **33:** 5112-5125.

52. Wei X, Huang H, Bao Y*, et al.* Novel long non-coding RNA AV310809 promotes TGF-beta1 induced epithelial-mesenchymal transition of human peritoneal mesothelial cells via activation of the Wnt2/beta-catenin signaling pathway. *Biochem Biophys Res Commun* 2019; **513:** 119-126.

53. Wang Z, Zhou Z, Ji W*, et al.* Silencing of lncRNA 6030408B16RIK prevents ultrafiltration failure in peritoneal dialysis via microRNA-326-3p-mediated WISP2 down-regulation. *Biochem J* 2020; **477:** 1907-1921.

54. Zhou Q, Zhang Y, Wang B*, et al.* KDM2B promotes IL-6 production and inflammatory responses through Brg1-mediated chromatin remodeling. *Cell Mol Immunol* 2020; **17:** 834-842.

55. Kottakis F, Polytarchou C, Foltopoulou P*, et al.* FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. *Mol Cell* 2011; **43:** 285-298.

**Table 1.** Demographic and clinical characteristics of participants, by ancestry, included in the genome wide association study of peritoneal solute transfer rate.

|  | **European** **(N=2212)** | **African** **(N=181)** | **Asian****(N=109)** | **Admixed/Other** **(N=348)** | **Total** **(N=2850)** |
| --- | --- | --- | --- | --- | --- |
| **Sex Female,** N (%) | 803 (36) | 102 (56) | 44 (40) | 135 (39) | 1084 (38) |
| **Age years,** Mean ± SD\* | 59.8 ± 15.8 | 52.7 ± 15.5 | 54.6 ± 15.8 | 54.7 ± 14.7 | 58.5 ± 15.8 |
| **Self-Reported Race,** N (%) |
|    White | 2212 (100) | 0 (0) | 0 (0) | 81 (23) | 2293 (80) |
|    Black | 0 (0) | 181 (100) | 0 (0) | 8 (2) | 189 (7) |
|  Asian | 0 (0) | 0 (0) | 109 (100) | 85 (25) | 194 (7) |
|    Native American/ Pacific Islander | 0 (0) | 0 (0) | 0 (0) | 29 (8) | 29 (1) |
|    Not Reported | 0 (0) | 0 (0) | 0 (0) | 145 (42) | 145 (5) |
| **Country,** N (%) Australia Belgium Canada Sweden UK USA | 34 (1)233 (11)135 (6)174 (8)1357 (61)279 (13) | 0 (0)11 (6)12 (7)0 (0)36 (20)122 (67) | 10 (9)8 (7)26 (24)0 (0)27 (25)38 (35) | 19 (5)6 (2)42 (12)16 (5)155 (44)110 (32) | 63 (2)258 (9)215 (8)190 (7)2575 (55)549 (19) |
| **Diabetes,** N (%)\*  | 636 (29) | 70 (39) | 44 (40) | 156 (45) | 906 (32) |
| **Cause of Kidney Failure,** N (%) |
|    Diabetes | 462 (21) | 37 (20) | 34 (31) | 126 (36) | 659 (23) |
|    Glomerular Disease | 463 (21) | 34 (19) | 21 (19) | 60 (17) | 578 (20) |
|    Hypertension | 215 (10) | 49 (27) | 17 (16) | 35 (10) | 316 (11) |
|    Cystic kidney disease | 235 (11) | 3 (2) | 1 (1) | 19 (6) | 258 (9) |
|    Other/Unknown | 837 (37) | 58 (32) | 36 (33) | 108 (31) | 1039 (37) |
| **BMI kg/m2,** Mean ± SD\* | 27.8 ± 5.8 | 28.6 ± 7.0 | 26.0 ± 6.1 | 27.8 ± 5.8 | 27.2 ± 6.0 |
| **Dialysate Dextrose for PET,** N (%) |
|    2.5% | 1709 (77) | 161 (89) | 79 (73) | 300 (86) | 2249 (79) |
|    4.25% | 358 (16) | 16 (9) | 22 (20) | 28 (8) | 424 (15) |
|    1.5% | 145 (7) | 4 (2) | 8 (7) | 20 (6) | 177 (6) |
|  **PD Start-PET Interval days, Median (IQR)** | 62 (37, 120) | 67 (39, 110) | 80 (52, 182) | 64 (37, 112) | 63 (28, 120) |
| **4 h D/P Creatinine,** Mean ± SD\* | 0.71 ± 0.13 | 0.68 ± 0.14 | 0.71 ± 0.11 | 0.68 ± 0.13 | 0.70 ± 0.13 |

Table 2. Regions of the genome showing the strongest association signals with peritoneal solute transfer rate as measured by 4-h D/P creatinine in participants of European ancestry (n=2212).

| **Genomic Region** | **Variant ID** | **Chromosome** | **Position** | **P value** | **Beta** **(95% CI)** | **R2\*** | **Minor Allele Frequency, %** | **Minor Allele** | **Major Allele** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| *LINC01800* 5’ ~40 kb*LINC01800* 5’ ~1 kb | rs76108553rs111976243 | 2 | 6503970065072210 | 9.2 x 10-72.4 x 10-6 | -0.05 (-0.07, -0.03)-0.05 (-0.07, -0.03) | 1.00.87 | 3.23.0 | TT | CC |
| *GIMAP6* 5’ ~12 kb\*\* | rs73474862rs12154435rs12154436rs1316352rs62491829rs35329030rs34030180 | 7 | 150341555150343708150343784150346270150349768150350564150350735 | 3.8 x 10-63.9 x 10-63.9 x 10-63.9 x 10-64.4 x 10-63.9 x 10-63.9 x 10-6 | -0.02(-0.03, -0.01)-0.02 (-0.03, -0.01)-0.02(-0.03, -0.01)-0.02 (-0.03, -0.01)-0.02(-0.03, -0.01)-0.02 (-0.03, -0.01)-0.02 (-0.03, -0.01) | 1.01.01.01.01.01.01.0 | 18.418.318.318.318.218.318.3 | CAATCGA | TGGCACG |
| *LINC01505* intron | rs13288836rs7039680rs11789496rs11789956rs11792623rs10512347rs1387591rs11794795rs4742997 | 9 | 109233842109243327109243344109244009109244902109245178109246563109254458109255208 | 1.2 x 10-61.2 x 10-63.9 x 10-71.5 x 10-62.0 x 10-61.5 x 10-67.6 x 10-72.3 x 10-63.6 x 10-6 | 0.02(0.01, 0.03)0.02(0.01, 0.03)0.02(0.01, 0.03)0.02(0.01, 0.03)0.02(0.01, 0.03)0.02(0.01, 0.03)0.02(0.01, 0.03)0.02(0.01, 0.03)0.02(0.01, 0.03) | 1.01.01.01.01.01.01.01.00.99 | 28.843.030.329.042.929.029.843.227.2 | ACTTCTGCT | CAGCTCCTC |
| *PCDH9* 5’~450kb | rs11840701rs11843673rs7325638rs7337043rs57521059 | 13 | 6825390468262519682631506826991168278456 | 4.7 x 10-64.4 x 10-64.4 x 10-64.0 x 10-64.6 x 10-6 | 0.02 (0.01, 0.03)0.02 (0.01, 0.03)0.02 (0.01, 0.03)0.02 (0.01, 0.03)0.02 (0.01, 0.03) | 1.01.00.990.990.99 | 19.819.819.819.819.8 | GCGCC | CTAGT |

All analyses are adjusted for age, sex, diabetes (yes/no), body mass index, log transformed PD start-PET interval, dialysate tonicity for PET, country of enrollment, and principal components (PC) 1-10 of ancestry, as covariates

\*R2=imputation quality

\*\*Regions/variants associated with evidence of eQTL RNAs in GTEx data

**Table 3.** Meta-analysis of stratified European (n=2212), African (n=181), Asian (n=109) and Admixed-Other (n=348) ancestry groups.

| **Genomic Region** | **Variant ID** | **Chromosome** | **Position** | **P value** | **Beta** **(95% CI)** | **R2\*** | **Minor Allele Frequency, %** | **Minor/****Major Allele** | **Direction****\*\*\*** | **n** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| *LINC01800* 5’ ~40 kb*LINC01800* 5’ ~1 kb | rs76108553rs111976243 | 2 | 6503970065072210 | * 1. x 10-6

2.4 x 10-6 | -0.05(-0.07, -0.03)-0.05(-0.07, -0.03) | 1.00.87 | 3.23.0 | T/CT/C | ???-???- | 22122212 |
| *LINC01561*, *PLPP4* 3’ ~5kb\*\* | rs2901257 | 10 | 122358463 | 4.5 x 10-6 | 0.02(0.01, 0.02) | 1.0 | 52.6 | A/G | ++-+ | 2850 |
| *KCNC2* 5’ `20 kb | rs117559199 | 12 | 75424551 | 3.9 x 10-6 | -0.04(-0.06, -0.03) | 0.87 | 3.8 | A/C | ?-?- | 2560 |
| *KDM2B* intron\*\* | rs28644184 | 12 | 121961947 | 2.9 x 10-6 | 0.02(0.01, 0.02) | 1.0 | 43.6 | T/C | ++++ | 2850 |

All analyses are adjusted for age, sex, diabetes (yes/no), body mass index, log transformed PD start-PET interval, dialysate tonicity for PET, country of enrollment, and principal components (PC) 1-10 of ancestry, as covariates

\*R2=imputation quality

\*\*Regions/variants associated with evidence of eQTL RNAs in GTEx data

\*\*\*1st position Asian, 2nd position Admixed/Other, 3rd position African, 4th European Ancestry, ? indicates not included, +/- Effect Direction

**Figure Legends**

**Figure 1:** **Flow diagram of building the study cohort.** Number of participants that were enrolled, that underwent genome wide genotyping, that were included in the final analytic cohort, and reasons for exclusion of participants at each step

**Figure 2:** **Results of** **genome wide association study (GWAS) as – log10 p plot (Manhattan plot).** Association of peritoneal solute transfer rate, as measured by 4-h D/P creatinine on peritoneal equilibration test, in: (A) 2212 individuals of European ancestry. The association of no single nucleotide variant reached genome-wide significance (p < 5 x 10-8). A total of 23 single nucleotide variants in four genomic regions demonstrated suggestive association (p < 5 x 10-6) with the phenotype of peritoneal solute transfer rate; (B) meta-analyses of GWAS in individuals of European, African, Asian, and admixed ancestry (n=2850). The association of no single nucleotide variant reached genome-wide significance (p < 5 x 10-8). A total of five single nucleotide variants at 4 loci demonstrated suggestive association (p < 5 x 10-6) with the phenotype of peritoneal solute transfer rate. All analyses are adjusted for age, sex, diabetes (yes/no), body mass index, dialysate tonicity used for the Peritoneal Equilibration Test, log transformed interval from start of PD to date of Peritoneal Equilibration Test in days, country of enrollment, and principal components (PC) 1-10 of ancestry, as covariates

**Figure 3A:** **Regional association plot of the *KDM2B* gene on chromosome 12 in which the intronic single nucleotide variant (rs28644184) with suggestive association is located.** Association of -log10 (p-values) with single nucleotide variants are plotted as points and the colors indicate the degree of linkage disequilibrium with the index variant.

**Figure 3B:** **Box plots for PSTR by *KDMB2* rs28644184 genotype**. The median (IQR) 4-h D/P creatine by genotype were: CC (n=917), 0.68 (0.59, 0.78); CT (n=1383), 0.71 (0.61, 0.80), and TT (n=550), 0.72 (0.63, 0.81).

**Figure 4:** **Association of polygenic risk with peritoneal solute transfer rate.** Association of tertiles of polygenic risk score with peritoneal solute transfer rate as measured by 4-h D/P creatinine on peritoneal equilibration test (n=299). The median (interquartile range) of 4-h D/P creatinine ratio: tertile 1, 0.67 (0.57-0.76); tertile 2, 0.73 (0.62-0.84), and tertile 3, 0.74 (0.66-0.82) (p=0.0002 for difference across tertiles).